Seloken ZOC 200 mg 28 tablets

Available at Pharmaegy Pharmacy. Use as directed by your doctor.

Seloken ZOC 200 mg Prolonged release tablets 28 tablets Composition: Metoprolol Succinate 190 mg Inactive ingredients: silicon dioxide, cellulose compounds, sodium stearyl fumarate, polyethylene glycol, titanium dioxide, paraffin. Properties: Metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta2-adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade. Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction. Indications: Hypertension Metoprolol succinate extended-release tablet is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. Angina Pectoris Metoprolol succinate extended-release tablets are indicated in the long-term treatment of angina pectoris. Heart Failure Metoprolol succinate extended-release tablet is indicated for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. Dosage and administration: Metoprolol succinate extended-release tablets are intended for once daily administration. For treatment of hypertension and angina, when switching from immediate release metoprolol to metoprolol succinate extended-release tablet, the same total daily dose of metoprolol succinate extended-release tablet should be used. Dosages of metoprolol succinate extended-release tablets should be individualized and titration may be needed in some patients. Metoprolol succinate extended-release tablets are scored and can be divided; however, the whole or half tablet should be swallowed whole and not chewed or crushed. Hypertension The usual initial dosage is 25 to 100 mg daily in a single dose, whether used alone or added to a diuretic. The dosage may be increased at weekly (or longer) intervals until optimum blood pressure reduction is achieved. In general, the maximum effect of any given dosage level will be apparent after 1 week of therapy. Dosages above 400 mg per day have not been studied. Angina Pectoris The dosage of metoprolol succinate extended-release tablets should be individualized. The usual initial dosage is 100 mg daily, given in a single dose. The dosage may be gradually increased at weekly intervals until optimum clinical response has been obtained or there is a pronounced slowing of the heart rate. Dosages above 400 mg per day have not been studied. If treatment is to be discontinued, the dosage should be reduced gradually over a period of 1–2 weeks. Heart Failure Dosage must be individualized and closely monitored during up-titration. Prior to initiation of metoprolol succinate extended-release tablet, the dosing of diuretics, ACE inhibitors, and digitalis (if used) should be stabilized. The recommended starting dose of metoprolol succinate extended-release tablet is 25 mg once daily for two weeks in patients with NYHA Class II heart failure and 12.5 mg once daily in patients with more severe heart failure. The dose should then be doubled every two weeks to the highest dosage level tolerated by the patient or up to 200 mg of metoprolol succinate extended-release tablet. If transient worsening of heart failure occurs, it may be treated with increased doses of diuretics, and it may also be necessary to lower the dose of metoprolol succinate extended- release tablet or temporarily discontinue it. The dose of metoprolol succinate extended-release tablet should not be increased until symptoms of worsening heart failure have been stabilized. Initial difficulty with titration should not preclude later attempts to introduce metoprolol succinate extended- release tablets. If heart failure patients experience symptomatic bradycardia, the dose of metoprolol succinate extended-release tablet should be reduced. Side effects: Central Nervous System: Reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrivcs. Cardiovascular: Intensification of AV block Hematologic: Agranulocytosis, nonthrombocytopenic purpura, thrombocytopenic purpura. Hypersensitive Reactions: Fever combined with aching and sore throat, laryngospasm, and respiratory distress. Others: Dizziness/vertigo, Bradycardia Contraindications: Metoprolol succinate extended-release tablet is contraindicated in severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome (unless a permanent pacemaker is in place) and in patients who are hypersensitive to any component of this product. Warnings and precautions: General: Metoprolol succinate extended-release tablets should be used with caution in patients with impaired hepatic function. In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent. Worsening cardiac failure may occur during up-titration of metoprolol succinate extended- release tablets. If such symptoms occur, diuretics should be increased and the dose of metoprolol succinate extended-release tablets should not be advanced until clinical stability is restored. It may be necessary to lower the dose of metoprolol succinate extended-release tablet or temporarily discontinue it. Such episodes do not preclude subsequent successful titration of metoprolol succinate extended-release tablets. Patients should be advised to take metoprolol succinate extended-release tablets regularly and continuously, as directed, preferably with or immediately following meals. If a dose should be missed, the patient should take only the next scheduled dose (without doubling it). Patients should not interrupt or discontinue metoprolol succinate extended-release tablets without consulting the physician. Patients should be advised (1) to avoid operating automobiles and machinery or engaging in other tasks requiring alertness until the patient’s response to therapy with metoprolol succinate extended-release tablets has been determined; (2) to contact the physician if any difficulty in breathing occurs; (3) to inform the physician or dentist before any type of surgery that he or she is taking metoprolol succinate extended-release tablets. Heart failure patients should be advised to consult their physician if they experience signs or symptoms of worsening heart failure such as weight gain or increasing shortness of breath. Caution should be exercised when metoprolol succinate extended-release tablets are administered to a nursing woman or woman during pregnancy. Storage: Store at a temperature not exceeding 25°C Package: Carton box holds 2 strips of 14 tablets and paper instructions